Skip to content

Study · Systematic review · 2026

4 results

GLP-1 receptor agonists for weight loss: A systematic review and meta-analysis of randomized controlled trials.

Ahmad N, Alruwayyes A, Alarjani A, Tawhari A, Aldosri A, Alahmari A, Balaha M

Medicine1 Mar 2026Cited by 10 (Europe PMC)

PMID41824845 (opens in a new tab)PMCIDPMC12991648 (opens in a new tab)DOI10.1097/md.0000000000047994 (opens in a new tab)PepBankPUB-41824845
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In a network meta-analysis of weight-loss trials, tirzepatide ranked among the highest of the GLP-1-based agents (SUCRA 91.2%).

    In plain wordsIn a network meta-analysis of weight-loss trials, tirzepatide ranked among the top GLP-1-based drugs.

    Peptide
    Tirzepatide
    Outcome
    Not applicableSUCRA ranking for weight loss
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    SUCRA
    91.2%
    tirzepatide

    Source sentences

    Summary
    In the network meta-analysis, tirzepatide and semaglutide ranked highest (surface under the cumulative ranking curve 91.2% and 85.4%, respectively).
    1 context sentence
    Summary · context
    We conducted a systematic review and meta-analysis of randomized controlled trials (PubMed, last 5 years, English language) evaluating GLP-1-based pharmacotherapies versus placebo or active comparators for weight loss.
  2. 02HumanSystematic reviewEfficacy outcome

    In a network meta-analysis of weight-loss trials, semaglutide ranked among the highest of the GLP-1-based agents (SUCRA 85.4%).

    In plain wordsIn a network meta-analysis of weight-loss trials, semaglutide ranked among the top GLP-1-based drugs.

    Peptide
    Semaglutide
    Outcome
    Not applicableSUCRA ranking for weight loss
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    SUCRA
    85.4%
    semaglutide

    Source sentences

    Summary
    In the network meta-analysis, tirzepatide and semaglutide ranked highest (surface under the cumulative ranking curve 91.2% and 85.4%, respectively).
    1 context sentence
    Summary · context
    We conducted a systematic review and meta-analysis of randomized controlled trials (PubMed, last 5 years, English language) evaluating GLP-1-based pharmacotherapies versus placebo or active comparators for weight loss.

Studies that did not test the peptide alone2

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 03HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome

    In adults with obesity, pooled GLP-1-based agents (including tirzepatide) raised the proportion achieving weight loss versus placebo across 16 placebo-controlled trials.

    In plain wordsIn adults with obesity, GLP-1-based drugs as a group helped more people lose weight than placebo across 16 trials.

    Peptide
    Tirzepatide
    Outcome
    IncreaseProportion achieving weight loss, pooled GLP-1-based agents versus placebo
    Study

    n = 7,024

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Weight loss proportion
    78.54%
    GLP-1-based agents
    Weight loss proportion
    26.53%
    placebo
    Pooled odds ratio
    11.37 ratio
    95% CI 8.10-15.98

    Source sentences

    Summary
    Across 16 placebo-controlled trials, a higher proportion of participants achieved weight loss with GLP- 1-based agents than with placebo: 78.54% (3231/4114) versus 26.53% (772/2910); pooled odds ratio: 11.37 (95% confidence interval: 8.10-15.98), P < .0001; I2 = 82%.
    2 context sentences
    Summary · context
    with tirzepatide and semaglutide demonstrating the greatest relative efficacy among agents evaluated.
    Summary · context
    We conducted a systematic review and meta-analysis of randomized controlled trials (PubMed, last 5 years, English language) evaluating GLP-1-based pharmacotherapies versus placebo or active comparators for weight loss.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  2. 04HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In adults with obesity, pooled GLP-1-based agents (including semaglutide) raised the proportion achieving weight loss versus placebo across 16 placebo-controlled trials.

    In plain wordsIn adults with obesity, GLP-1-based drugs as a group helped more people lose weight than placebo across 16 trials.

    Peptide
    Semaglutide
    Outcome
    IncreaseProportion achieving weight loss, pooled GLP-1-based agents versus placebo
    Study

    n = 7,024

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Weight loss proportion
    78.54%
    GLP-1-based agents
    Weight loss proportion
    26.53%
    placebo
    Pooled odds ratio
    11.37 ratio
    95% CI 8.10-15.98

    Source sentences

    Summary
    Across 16 placebo-controlled trials, a higher proportion of participants achieved weight loss with GLP- 1-based agents than with placebo: 78.54% (3231/4114) versus 26.53% (772/2910); pooled odds ratio: 11.37 (95% confidence interval: 8.10-15.98), P < .0001; I2 = 82%.
    2 context sentences
    Summary · context
    with tirzepatide and semaglutide demonstrating the greatest relative efficacy among agents evaluated.
    Summary · context
    We conducted a systematic review and meta-analysis of randomized controlled trials (PubMed, last 5 years, English language) evaluating GLP-1-based pharmacotherapies versus placebo or active comparators for weight loss.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.